Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Verrica Pharmaceuticals Inc. - Common Stock
(NQ:
VRCA
)
0.6438
-0.0185 (-2.79%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 19, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Verrica Pharmaceuticals Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
April 02, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA
March 26, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
VERRICA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA
March 08, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
February 29, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Earnings Scheduled For February 29, 2024
February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.
Via
Benzinga
Earnings Outlook For Verrica Pharmaceuticals
February 28, 2024
Via
Benzinga
7 Analysts Have This to Say About Verrica Pharmaceuticals
October 12, 2023
Via
Benzinga
Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference
February 27, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024
February 22, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
VERRICA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA
February 14, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition
February 05, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH™ from Centers for Medicare and Medicaid Services
January 29, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
7 Potential Short-Squeeze Stocks Poised for Rapid Gains
January 22, 2024
Giving the bears a rough time can yield massive gains for contrarians, thus drawing attention to these potential short-squeeze stocks.
Via
InvestorPlace
Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma
January 05, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH™ for the Treatment of Common Warts
January 04, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH™
January 03, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Top 4 Health Care Stocks That May Crash This Month
December 20, 2023
As of Dec. 20, 2023, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Via
Benzinga
Insiders Buying Pfizer And 3 Other Stocks
December 20, 2023
Although U.S. stocks closed higher on Tuesday, there were a few notable insider trades.
Via
Benzinga
Why Is Verrica Pharmaceuticals (VRCA) Stock Up 40% Today?
December 15, 2023
With Verrica Pharmaceuticals releasing positive Phase 3 trial results for a skin disease therapeutic, VRCA stock skyrocketed in response.
Via
InvestorPlace
Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) Near the Top of Equities by Percentage Gain on 12/15
December 15, 2023
Via
Investor Brand Network
Why Quanex Building Products Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
December 15, 2023
Shares of Quanex Building Products Corporation (NYSE: NX) moved lower during Friday’s session after the company reported fourth-quarter financial results. Quanex Building Products shares fell 10.7% to...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
December 15, 2023
Via
Benzinga
Why Is Skin Disease-Focused Verrica Pharmaceuticals Stock Trading Higher Today?
December 15, 2023
Verrica Pharmaceuticals Inc's (NASDAQ: VRCA) development and commercialization partner, Torii Pharmaceutical Co Ltd, reported topline results from its Phase 3 trial of TO-208 (referred to as VP-102 and...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
December 15, 2023
Via
Benzinga
Verrica Pharmaceuticals’ Development and Commercialization Partner, Torii Pharmaceutical Co., Ltd., Announces Positive Top-line Results from a Confirmatory Phase 3 Trial of TO-208 for the Treatment of Molluscum Contagiosum in Japan
December 15, 2023
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Announces Presentation at the Jefferies Global Healthcare Conference in London
November 10, 2023
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Reports Third Quarter 2023 Financial Results
November 09, 2023
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals to Provide a Corporate Update and Report Third Quarter Financial Results on November 9, 2023
October 25, 2023
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Earnings Scheduled For November 9, 2023
November 09, 2023
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on revenue of $265.00 million.
Via
Benzinga
Verrica Pharmaceuticals to Host Virtual KOL Event Discussing the Approval of YCANTH™ (Cantharidin) Topical Solution for the Treatment of Molluscum on October 11, 2023
September 27, 2023
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.